ESR1 and breast carcinoma: Interestingly, our study confirms that upon the development of PLB resistance, PLB treatment loses its effect of reducing the expression of pRb (S807) protein levels, as evident in PLB-resistant ER+ breast cancer MCF7 cells (Figure 1A).